Botty van den Bruele, A., Ferraro, E., Sevilimedu, V., Hogan, M. P., Javed-Tayyab, S., Le, T., … Sacchini, V. (2021). Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy? Breast Cancer Research and Treatment, 189(2), 307–315. https://doi.org/10.1007/s10549-021-06331-3

Botty van den Bruele, Astrid, Emanuela Ferraro, Varadan Sevilimedu, Molly P. Hogan, Sidra Javed-Tayyab, Tiana Le, Monica N. Fornier, Monica Morrow, and Virgilio Sacchini. “Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?” Breast Cancer Research and Treatment 189, no. 2 (September 2021): 307–15. https://doi.org/10.1007/s10549-021-06331-3.

Botty van den Bruele A, Ferraro E, Sevilimedu V, Hogan MP, Javed-Tayyab S, Le T, et al. Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy? Breast Cancer Research and Treatment. 2021 Sep;189(2):307–15.

Botty van den Bruele, Astrid, et al. “Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy?” Breast Cancer Research and Treatment, vol. 189, no. 2, Springer Science and Business Media LLC, Sept. 2021, pp. 307–15. Crossref, doi:10.1007/s10549-021-06331-3.

Botty van den Bruele A, Ferraro E, Sevilimedu V, Hogan MP, Javed-Tayyab S, Le T, Fornier MN, Morrow M, Sacchini V. Does preoperative MRI accurately stratify early-stage HER2 + breast cancer patients to upfront surgery vs neoadjuvant chemotherapy? Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021 Sep;189(2):307–315.